WuXi AppTec: Second-quarter Revenue Still Expected to Grow 63% to 65%

On the evening of June 5, WuXi PharmaTech announced that the company's current production and operation activities in Shanghai have basically returned to normal. From April to May 2022, the company will continue to strengthen the integrated CRDMO (contract research, development and production) and CTDMO (contract testing, research and development and production) business models, and actively cooperate with the implementation of the new crown pneumonia epidemic prevention and control measures in Shanghai to fully Give full play to the advantages of global layout, multi-location operation and full industry chain coverage, formulate and efficiently implement business continuity plans in a timely manner, and ensure the achievement of the company's overall performance goals.

In this regard, WuXi PharmaTech expects that its revenue in the second quarter of 2022 will still achieve a growth of 63%-65% as previously announced, and the company continues to be confident in its goal of achieving a revenue growth of 65%-70% for the full year of 2022.

WuXi AppTec reminds that the above-mentioned business performance outlook for the second quarter of 2022 and the full year of 2022 is based on the company's current orders in hand. The profit forecast of the annual operating performance does not constitute the company's substantial commitment to investors. In addition, the above-mentioned relevant operating performance outlook is based on the premise of the stabilization or improvement of the global new crown virus epidemic, the stable development of the global pharmaceutical industry, the stability of the international trade environment and the regulatory environment in the countries where major operations are located, etc. Whether it can be realized depends on various changes in the internal and external environment, etc. There are large uncertainties due to the influence of factors.